Capricor Therapeutics Inc CAPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CAPR is a good fit for your portfolio.
News
-
Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?
-
Capricor Therapeutics to Present at Upcoming Investor Conferences
-
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
-
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
-
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
-
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
-
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine
Trading Information
- Previous Close Price
- $4.94
- Day Range
- $4.70–5.02
- 52-Week Range
- $2.68–8.22
- Bid/Ask
- $4.75 / $5.29
- Market Cap
- $151.84 Mil
- Volume/Avg
- 478,470 / 306,088
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 102
- Website
- https://www.capricor.com
Comparables
Valuation
Metric
|
CAPR
|
ETNB
|
CBAY
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.81 | 1.58 | 12.65 |
Price/Sales | 5.25 | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
CAPR
ETNB
CBAY
Financial Strength
Metric
|
CAPR
|
ETNB
|
CBAY
|
---|---|---|---|
Quick Ratio | 1.59 | 19.55 | 10.70 |
Current Ratio | 1.63 | 20.04 | 10.96 |
Interest Coverage | — | −31.54 | −5.27 |
Quick Ratio
CAPR
ETNB
CBAY
Profitability
Metric
|
CAPR
|
ETNB
|
CBAY
|
---|---|---|---|
Return on Assets (Normalized) | −30.28% | −28.69% | −30.06% |
Return on Equity (Normalized) | −179.23% | −32.35% | −51.97% |
Return on Invested Capital (Normalized) | −139.50% | −32.89% | −30.87% |
Return on Assets
CAPR
ETNB
CBAY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bjnpvlmf | Kbh | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kdpsgkttp | Wsqvf | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Msfbgbcz | Nzhxqy | $98.8 Bil | |
MRNA
| Moderna Inc | Fzljkvy | Gkgzs | $38.8 Bil | |
ARGX
| argenx SE ADR | Cpnvsfcb | Wpb | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Yrnzvysc | Lnj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hqwgldph | Zxwbnj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twsqknnfc | Tsffbjd | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bgrgcmqwd | Nkxbqn | $12.4 Bil | |
INCY
| Incyte Corp | Wqhfzcy | Wdtct | $11.9 Bil |